/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Climb Bio Inc Share Price Today: Live Updates & Key Insights

Climb Bio Inc share price today is $7.27, up -0.95%. The stock opened at $7.22 against the previous close of $7.33, with an intraday high of $7.26 and low of $6.9.

Climb Bio Inc Share Price Chart

style
pb-0

Climb Bio Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Climb Bio Inc Share Price Performance

$7.27 -0.0095(-0.95%) CLYM at 13 Mar 2026 12:29 PM Biotechnology
Lowest Today 6.9
Highest Today 7.26
Today’s Open 7.22
Prev. Close 7.33
52 Week High 8.04
52 Week Low 1.05
Day’s Range: Low 6.9 High 7.26
52-Week Range: Low 1.05 High 8.04
1 day return -
1 Week return +0.69
1 month return +27.86
3 month return +91.04
6 month return +255.39
1 year return +443.07
3 year return -
5 year return -
10 year return -

Climb Bio Inc Institutional Holdings

Climb Bio Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Climb Bio Inc Fundamentals

Market Cap 499.79 M

PB Ratio 2.1819

PE Ratio 0.0

Enterprise Value 249.60 M

Total Assets 167.74 M

Volume 401155

Climb Bio Inc Company Financials

About Climb Bio Inc & investment objective

Company Information Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow